Shanghai Ruixing Gene Technology

Shanghai Ruixing Gene Technology is a clinical-stage biotechnology company specializing in the development of next-generation Adeno-Associated Virus (AAV) gene therapies. The company leverages its proprietary AAV vector discovery platform to create highly efficient, tissue-specific delivery vehicles for treating genetic and chronic diseases. Its primary focus areas include ophthalmology, neurology, and metabolic disorders, with a lead program, RX-101, targeting neovascular age-related macular degeneration. Ruixing Gene aims to overcome the limitations of current gene therapies by improving safety profiles and enhancing therapeutic efficacy through optimized vector design. The company is headquartered in Shanghai and supported by leading venture capital firms.